Patent · US Active

HTP platform for the genetic engineering of Chinese hamster ovary cells

US10988761B2 · kind B2 · utility

0Cited by
11References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 20, 2020
Grant dateApr 27, 2021
Priority date—
Expiry dateJul 20, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/20
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Presented herein is a high-throughput (HTP) genomic engineering platform for improving the production of therapeutic proteins in Chinese hamster ovary (CHO) cells. The disclosed HTP genomic engineering platform is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. The platform utilizes a unique suite of HTP genetic engineering tools to explore the genomic landscape associated with therapeutic protein production pathways, in order to unravel the biological drivers and disentangle the uncharacterized genetic architecture responsible for optimizing therapeutic protein production in CHO cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.